Administrative Core

行政核心由U54的主要研究员Ernest Martinez博士领导。(PI大学， 加州，滨江[UCR]）和医学博士维多利亚塞瓦尔特。(PI City of Hope综合癌症中心 [CoHCCC]）。行政核心的总体使命是促进U54 UCR-CoH综合 癌症中心（CoHCCC）通过提供高质量的科学领导，行政支持， 和财政管理。行政核心支持U54规划，优先事项的制定和实施。 核心将支持外部咨询委员会（EAB）、内部咨询委员会（IAB）和 社区咨询委员会（CAB）指导并提供建议和监督我们的U54。我们的EAB成员是 国家领导人和领导自己的P20和U54赠款，重点是消除差距。EAB领导人包括 Robert Winn，医学博士（梅西综合癌症中心），劳拉Fejerman，博士(UC Davis），Lucio Miele， M.D. (LSU)Melissa Simon，Ph.D.（Lurie综合癌症中心）。我们的实验室成员 UCR和CoHCCC的领导人。来自UCR的IAB领导人包括博士Kelechi Kalu，博士。副教务长 政治学教授; Frances Sladek博士，细胞生物学和毒理学教授。IAB领导人从 CoHCCC包括Steven Forman博士，CAR-T细胞治疗项目的CoHCCC负责人和贝克曼 治疗主任;琳达Malkas博士，翻译科学和对外事务院长。确保 为了指导下一代U54领导者，我们在IAB中包括两名早期研究人员（ESI） 在我们的实验室工作，包括杰纳·穆恩博士加州大学洛杉矶分校的基础调查员和Ana Tergas医学博士，一 有前途的临床试验者和来自CoHCCC的拉丁裔研究员。我们将与规划和 评估核心（PEC），并作为U54的监督机构。IAB将每年两次与U54领导人会面- 或在需要时更频繁地提供战略方向、政策制定和对U54的评估 合作项目和核心。PEC、IAB和EAB将对全面和试点项目进行年度审查， 丹CAB将评估项目和核心-特别是我们的社区外展核心，并评估我们的 指导和促进URM ESI职业发展的能力。EAB、IAB和CAB将与U54项目联合举行会议 和核心领导人评估整体进展和影响癌症健康差异和药物治疗差异的能力 开发和临床试验。

The Administrative Core is led by the U54’s Principal Investigators, Ernest Martinez, Ph.D. (PI, University of California, Riverside [UCR]) and Victoria Seewaldt, M.D. (PI, City of Hope Comprehensive Cancer Center [CoHCCC]). The overall mission of the Administrative Core is to facilitate the U54 UCR – CoH Comprehensive Cancer Center (CoHCCC) U54 partnership by providing high-quality scientific leadership, administrative support, and fiscal management. The Administrative core supports U54 planning, priority-setting, and implementation. The Core will support the ability of the External Advisory Board (EAB), Internal Advisory Board (IAB), and Community Advisory Board (CAB) to guide and provide advice and oversight of our U54. Our EAB members are national leaders and lead their own P20 and U54 grants focusing on eliminating disparities. EAB leaders include Robert Winn, M.D. (Massey Comprehensive Cancer Center), Laura Fejerman, Ph.D. (UC Davis), Lucio Miele, M.D. (LSU), and Melissa Simon, Ph.D. (Lurie Comprehensive Cancer Center). Our IAB members are senior leaders at both UCR and CoHCCC. IAB leaders from UCR include Dr. Kelechi Kalu, Ph.D. and Vice Provost and Professor of Political Science; Dr. Frances Sladek, Professor of Cell Biology and Toxicology. IAB leaders from CoHCCC include Steven Forman, Ph.D., CoHCCC leader of CAR-T cell therapeutics program and Beckman Therapeutic Director; Linda Malkas, Ph.D., Dean of Translational Science and External Affairs. To ensure mentorship of the next generation of U54 leaders, we include on our IAB, two early-stage investigators (ESIs) serve on our IAB, this includes Jernej Murn, Ph.D., a basic investigator from UCR and Ana Tergas, M.D., a promising clinical trialist and Latina researcher from CoHCCC. Together, we will work with the Planning and Evaluation Core (PEC) and serve as the U54’s oversight body. The IAB will meet with U54 leaders twice-year - or more frequently if needed - to provide strategic direction, policy development, and evaluation of our U54 Partnership Projects and Cores. The PEC, IAB, and EAB will perform yearly review of Full and Pilot projects and Cores. The CAB will evaluate projects and cores – particularly our Community Outreach Core and assess our ability to mentor and promote the careers of URM ESI. The EAB, IAB, and CAB will meet jointly with U54 project and core leaders to assess overall progress and ability to impact cancer health disparities and disparities in drug development and clinical trials.